Dr. Jay E. Shankar, MD
Nephrology (Kidney) (Nephrology Physician)
12675 Hesperia Rd
Victorville, CA 92395
Who else practices at this address →
San Bernardino County includes primary care (5% of residents) and mental health (26% of residents) shortage areas. About shortage areas
- Medicare participating
At a glance
- Years since graduation
- 52
- In the NPI registry since
- 2006
- Medicare patients seen, 2024
- 250
Licensed in California since 1983, according to the Medical Board of California. We show license dates only for the states that publish them in bulk; see which states do. For other states, check the state medical board.
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 2006Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Medicare’s Care Compare data doesn’t list this clinician’s medical school. Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Nephrology Physician primary
CA license A40224 (first issued 1983; current) -
Internal Medicine Physician
CA license A40224 (first issued 1983; current)
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Providence St Mary Medical Center Apple Valley, CA
- Desert Valley Hospital Victorville, CA
- Barstow Community Hospital Barstow, CA
- Bear Valley Community Hospital Big Bear Lake, CA
Medical groups
- High Desert Nephrology Medical Associates Inc (6 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 250
- Services billed
- 1,242
- Patients’ average age
- 73
| Service | Times | Patients |
|---|---|---|
| Established patient office or other outpatient visit, 30-39 minutes | 379 | 180 |
| Dialysis services, 4 or more physician visits per month (20 years or older) | 234 | 94 |
| Home dialysis services per month (20 years or older) | 81 | 13 |
| New patient office or other outpatient visit, 45-59 minutes | 37 | 37 |
| Dialysis services, 2-3 physician visits per month (20 years or older) | 22 | 16 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Furosemide Other prescribers in Victorville, CA | 297 |
| Metoprolol Succinate Other prescribers in Victorville, CA | 276 |
| Losartan Potassium Other prescribers in Victorville, CA | 255 |
| Sevelamer Carbonate Other prescribers in Victorville, CA | 241 |
| Amlodipine Besylate Other prescribers in Victorville, CA | 232 |
| Allopurinol Other prescribers in Victorville, CA | 156 |
| Nifedipine Er (nifedipine) Other prescribers in Victorville, CA | 152 |
| Cinacalcet Hcl Other prescribers in Victorville, CA | 117 |
| Clonidine Hcl Other prescribers in Victorville, CA | 109 |
| Prosol (parenteral amino acid 20% no.1) | 107 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 7 companies reported 21 payments worth $674 in total to this clinician.
| Akebia Therapeutics Inc | $284 |
|---|---|
| Otsuka America Pharmaceutical, Inc. | $174 |
| Calliditas Therapeutics US Inc. | $73.94 |
| Ardelyx, Inc. | $64.53 |
| Scpharmaceuticals Inc. | $32.95 |
| Apellis Pharmaceuticals, Inc. | $26.47 |
| AstraZeneca Pharmaceuticals LP | $18.07 |
| Food and Beverage | $664 |
|---|---|
| Education | $10.57 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Akebia Therapeutics Inc Jul 16, 2025 | Education Vafseo · Nephrology · in-kind | $10.57 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 5 industry-funded studies in 2025, from 3 companies. The companies reported $908,202 in research payments for these studies, mostly to the institutions running them.
- Combined Dose-Finding and CV Outcomes Study With CSL300 (Clazakizumab) in Adult Subjects With ESKD Undergoing Dialysis (POSIBIL6ESKD)
Csl Behring · Recruiting · NCT05485961 - The Effect of Retatrutide Once Weekly on Cardiovascular Outcomes and Kidney Outcomes in Adults Living With Obesity (TRIUMPH-Outcomes)
Eli Lilly and Company · Active, not recruiting · NCT06383390 - A Phase III, Randomised, Multicentre, Double-blind Study to Evaluate the Efficacy, Safety and Tolerability of Zibotentan/Dapagliflozin FDC Compared to Dapagliflozin Alone in Participants with Chronic Kidney Disease an…
AstraZeneca Pharmaceuticals LP - A phase I and IIa randomized,double blind,placebo controlled study to evaluate the safety and pharmacokinetics of AZD7760 in healthy participants and in patients with end stage kidney disease receiving hemodialysis th…
AstraZeneca Pharmaceuticals LP - The purpose of the D4325C00007 study is to identify and characterise patients with known or newly diagnosed CKD for possible participation in future renal clinical studies and to obtain an overview on current treatmen…
AstraZeneca Pharmaceuticals LP
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.